Volume 9, Issue 3, March – 2024 International Journal of Innovative Science and Research Technology
ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24MAR1293

Pharmacoeconomics in Healthcare

Apoorva Mahendrakar[1*]; Hrithik Ajja[1]; Aashutosh Sinwal[2]; Ishu[2]; Nisha[2]; Priyanshi Jain[2]
[1]Malla Reddy College of Pharmacy, Maisammaguda, Hyderabad, Telangana, India- 500100
[2]Pharm D, School of Pharmaceutical Sciences, Jaipur National University, Jaipur, Rajasthan, India,302017

Corresponding Author: Apoorva Mahendrakar*
Malla Reddy College of Pharmacy, Maisammaguda,
Hyderabad, Telangana, India- 500100

Abstract:- Pharmacoeconomics is the study of the cost-effectiveness and accessibility of pharmaceutical treatments from the perspective of both individuals and the healthcare system as a whole. This field can help policymakers and healthcare providers make more informed decisions about patient care. The field of health economics saw its inaugural publication in 1973, while the idea of cost-benefit and cost-effectiveness analysis was originally put forth by University of Minnesota researchers McGhan, Rowland, and Bootman in 1978. In pharmacoeconomics, four main categories exist cost-utility analysis, cost-minimization analysis, cost-benefit analysis, and cost-effectiveness analysis. Pharmacoeconomics was originally an applied discipline. Because of their relative youth, health economics, and pharmacoeconomics are still in the process of refining and evaluating their methods. Health economics has a lot of issues that make it hard to use in real life. The field of pharmacoeconomics offers valuable insights that healthcare practitioners can use in their practice. Drug policy and clinical decision-making are both aided by pharmacoeconomics.

Keywords:- *Pharmacoeconomics, Cost-Minimization Analysis, Cost-Utility Analysis, Cost-Effectiveness Analysis, Cost-Benefit Analysis, Quality-Adjusted Life Years.*

I. INTRODUCTION

A subfield of health economics known as "pharmacoeconomics" studies the effects and costs of pharmaceutical goods and services. Research into drugs, their manufacturing, delivery, storage, price, and finally, their consumption, are all interconnected in this economic model. When it comes to pharmaceutical goods, services, and programs, pharmacoeconomics is the study of how they affect people, businesses, and markets. To put it simply, pharmacoeconomics is the study of the cost-effectiveness and accessibility of pharmaceutical treatments from the perspective of both individuals and the healthcare system as a whole. [1] This field can help policymakers and healthcare providers make more informed decisions about patient care. For healthcare decision-makers, pharmacoeconomic methods include cost-minimization, cost-effectiveness, cost-utility, cost-benefit, cost-of-illness, cost-consequence, and other useful economic analytic approaches. Achieving sufficient reimbursement and payment for services is increasingly dependent on conducting cost-effectiveness studies of pharmacological choices. Additionally, pharmacoeconomic methods aid in validating the costs and advantages of different pharmaceutical services and therapies, which may aid in determining the relevance of those options and aiding in the proper allocation of resources in dynamic healthcare systems.[2]

II. GENESIS OF PHARMACOECONOMICS

In the early 1960s, the field of pharmacy was officially acknowledged as a clinical profession inside the healthcare system. Clinical pharmacy, drug information, and pharmacokinetics are three areas of the pharmaceutical sciences that emerged during this period and are integral to pharmacy science and education. Rooted in the 1970s, pharmacoeconomics emerged in the 1980s.[3] The field of health economics saw its inaugural publication in 1973, while the idea of cost-benefit and cost-effectiveness analysis was originally put forth by University of Minnesota researchers McGhan, Rowland, and Bootman in 1978. The results of tailoring aminoglycoside doses to critically burned patients with gram-negative septicemia were evaluated in a 1979 early research publication in the field of pharmacy that included complex pharmacokinetic protocols and cost-benefit analysis.[4] A specialist pharmacy academic program was established in 1983 at Ohio State University College of Pharmacy to offer a general introduction to cost-benefit and cost-effective analysis in healthcare, particularly as it pertains to the provision of pharmaceutical treatment. With its original definition as "analysis of the costs of drug therapy to healthcare systems and society," the term "pharmacoeconomics" didn't make it into print until Townsend's 1986 publication brought attention to the need to establish research initiatives in this emerging field. The first issue of the journal "Pharmacoeconomics" appeared in 1992.[5]

➢ *Pharmacoeconomics Evaluations: Key Components*

To provide a decision-making framework, economic evaluations compare and contrast at least two health interventions to determine the costs and outcomes of various technologies in a certain population. In this study, "costs" and "outcomes" play crucial roles. Those individuals or groups that are most likely to gain from a health intervention

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24MAR1293

are called the target population. In the economic evaluation, interventions (such as medications, vaccines, medical procedures, or services) were used as comparators. One way to look at the costs and benefits of health care is from a variety of perspectives. During an economic analysis, the temporal horizon is used to compute the costs and outcomes, which are also known as benefits and consequences. A decision's opportunity cost is the value of a benefit that could have been achieved had a different choice been selected.[6] In economic analysis, "costs" mean the monetary part. Intangible costs, as well as direct and indirect medical and non-medical expenditures, are a part of it. Healthcare or humanistic outcomes are the anticipated results of an intervention; they are also known as benefits or consequences. The term "willingness to pay" refers to a method of gathering information on people's financial willingness to pay for a specific intervention or service. A person's time preferences can be taken into consideration through the application of discounting. A positive rate of time preference dictates that most people would rather have advantages sooner rather than later and that they would rather bear expenses later rather than sooner. Decision trees and simulation models are two examples of modeling procedures that can operationalize decision analyses derived from economic evaluations. Uncertainty in economic evaluation outcomes can be represented through sensitivity analysis. Multiway sensitivity analysis, probabilistic sensitivity analysis, threshold sensitivity analysis, and one-way basic sensitivity analysis are the four significant varieties of sensitivity studies.[7]

When it comes to pharmacoeconomic studies, the rules for how they should be conducted and reported are made by the Professional Society for Health Economics and Outcomes Research (ISPOR). These components make up the CHEERS statement, which is a condensed version of the original. Researchers in the field of pharmacy practice should take into account the following two ideas, however, while conducting an economic evaluation.[6,7]

- When one choice is made, additional benefits that may have been had from other possibilities are lost. This is called opportunity cost. Players will allocate funds to one healthcare activity at the expense of others due to resource scarcity, according to this theory. So, to make smarter decisions, it's helpful to know what opportunities can be lost if one technology is chosen over another.
- A non-welfarist viewpoint on decision-making is known as "willingness to pay" (WTP). According to this view, the best health intervention is the one that, up to a certain point, reaps the greatest benefit for the greatest number of patients. Using a WTP threshold, decision-makers can determine the point at which it is worthwhile to pay more for additional value.[8]

Expenses, or monetary consequences, are typically broken down into direct, indirect, medical, non-medical, and intangible expenses. This is the initial stage in any cost study. The term "direct costs" describes the money that goes straight into healthcare services, meaning they are directly related to how patients are treated. Direct costs can be categorized as either medical or non-medical based on whether they pertain to specific medical procedures or other related expenses. Costs can be categorized as either fixed or variable based on changes in the amount of services supplied, due to the flexibility in medical care delivery.[9] Indirect expenses include things like patients', families', and society's lost wages or production as a result of patients' illnesses. The amount of pain and suffering caused by a medical condition or treatment is an example of an intangible cost. These are typically hard to pin down and put a price on. Nonetheless, these details were more and more incorporated into evaluations by researchers undertaking investigations from a social viewpoint.[10]

The second part of any economic analysis is the anticipated advantages of an intervention or the outcome to be examined. The goal of "benefit" measurement is to be as all-encompassing as possible by including all of how the health intervention affects the patient's life. The value gained from selecting option A instead of B is seen as the defined benefits. Natural units (such as years of life gained or events prevented like strokes, surgeries, or peptic ulcer healing) and utility units (which try to encompass as much of the notion of 'value' as possible) are two ways these interventions can be measured. Utility units can take into account things like the quality of a state of health rather than just its quantity or the satisfaction that comes from going from one state of health to another. A measure of 'quality of life' in various illness stages is sometimes used to inform these utility estimations.[11]

III. METHODS OF PHARMACOECONOMIC ANALYSIS

The goal of pharmacoeconomic studies is to compare the financial, medical, and subjective results of various treatments. To gain more support from healthcare professionals, administrators, and the general public, it is helpful to show how novel therapies affect costs using the evaluation methods outlined. In pharmacoeconomics, four main categories exist:

- Cost-Utility Analysis
- Cost-Minimization Analysis
- Cost-Benefit Analysis
- Cost-Effectiveness Analysis

When multiple treatment options provide almost the same results, the cheapest one should be considered using cost-minimization analysis (CMA). The goal of cost-benefit analysis (CMA) in drug selection is to identify the treatment option with the lowest total cost. The expense of both dosing and preparation is also reflected in it.[12] When determining how much a medicine will cost, this is the approach that is most commonly utilized. Only two drugs with similar therapeutic effects and doses can be compared using this method. Thus, when comparing therapeutic equivalents and generic versions of medications, this strategy is at its best. If therapeutic equivalent cannot be proven, then cost-minimization analysis is unacceptable because there is often no verifiable equivalence between two products.[13] To back up economic assessments, there are a lot of clinical evidence

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24MAR1293

sources; but, the "gold standard" is usually the randomized controlled trial (RCT), which keeps everything constant except the medicine being tested. It is not feasible to conduct a CMA in conjunction with an RCT because of the lack of certainty regarding the equivalence of the health outcomes being compared, which arises from the fact that clinical trial results cannot be predicted in advance. Thus, CMAs are not the starting point for prospective economic evaluations; health economists will only use CMAs as a methodology if the produced health outcomes are shown to be "identical or similar" in an empirical setting. The CMA is often depicted as the "poor relation" of health economic methodology; critics argue that it lacks the theoretical rigor to be seriously examined alongside other, more complex approaches. However, health economists should realize and accept that CMA has robust theoretical foundations like any other economic evaluation approach.[11,13]

When there are multiple treatment options with varied efficacies, cost-effectiveness analysis (CEA) comes into play. The expenses of the condition's treatment, both directly and indirectly (via work impact), are stated in the numerator, while the benefit to the patient, measured in life-years saved or healthy days, is stated in the denominator. In addition, the incremental cost-effectiveness studies compare the two treatments.[13]

Cost-effectiveness ratio = Cost/Outcome

A more holistic view of medication expenses is required for cost-effectiveness analysis (CEA). The monetary cost and the clinical outcome (such as the number of lives saved, complications avoided, or diseases cured) are two separate but related metrics. Thus, CEA is a measure of the additional cost of achieving a specific health outcome that differs for each medication indication. CEA is a method for comparing many choices by calculating the relative importance of each option's cost and health efficacy. The overarching purpose of CEA is to develop a unified metric—the ICER—that connects the value of a treatment option to its differential cost. The ICER is determined using the following formula when comparing two options: The health resource costs, which are expressed in monetary terms and represent the difference in costs between treatment 1 and treatment 2, are the numerator in medical or pharmacoeconomic cost-effectiveness analyses.[12,14] The non-monetary changes in health effectiveness values implied by selecting treatment 1 over treatment 2 constitute the differential benefits of the various options (the denominator) in cost-effectiveness analysis. Lives saved, years lived, disease episodes prevented, and other clinical or health outcomes are common ways to assess these results. The cost-benefit analysis takes into account the monetary worth of both the costs and benefits of interventions, in contrast to CEA. The incremental cost-effectiveness ratio (ICER) is a metric for comparing medical intervention techniques that CEA uses. Data from clinical trials can be used for these kinds of studies if there is information about the trials' costs and their efficacy. Another typical way is to utilize decision analysis models to combine data from various sources. Interpreting their findings can be difficult because there isn't a universally accepted definition of "cost-effectiveness" and because CEAs might use a wide range of health outcomes as their effectiveness term.[15] An economic analysis known as a cost-benefit analysis (CBA) takes monetary values for both the costs and the outcomes. The investment in the therapy is defined by the denominator, while the benefit from the treatment is stated in the numerator. To directly calculate the net monetary cost of reaching a health outcome, cost-benefit analysis (CBA) is used to value both incremental costs and outcomes in monetary terms.[16] The societal productive value of a life-year may be considered as a cost when calculating a gain in life-years. One approach to evaluating improvements to quality of life is the willingness-to-pay method, which determines how much people are prepared to spend in exchange for a benefit to their quality of life.[17]

By comparing the incremental cost of a program from a particular perspective to the incremental health gain indicated in quality-adjusted life years (QALYs), cost-utility analysis (CUA) is a type of economic analysis. Utility costs, measured in terms of things like quantity and quality of life, are calculated using CUA. When comparing two treatments or procedures with potentially varying benefits, cost-utility analysis is more appropriate than cost-benefit analysis. Using a single health outcome category, CUA expresses the value for money. It is common practice to express the ICER in this context as the incremental cost to achieve an additional QALY.[17,18] This method takes a holistic view, measuring improvements in quality of life alongside advances in survival time. On a scale from 0 (death) to 1 (ideal quality of life), an improvement in QoL is represented as a utility value. Using incremental cost-utility ratios, we can compare the expense of a drug's therapy to that of alternative health therapies that provide the same or equivalent benefits.[19]

- *Impact of Pharmacoeconomics on Healthcare*

Pharmacoeconomics was originally an applied discipline. In the years leading up to the new millennium, a plethora of new products—mostly pharmaceuticals—came to market at a dizzying rate, prompting the widespread belief that healthcare budgets were under pressure due to the outsized spending on pharmaceuticals compared to other areas of healthcare. Suddenly, payers wanted manufacturers to explain their products' high prices, so they turned to economics, clinical experts, and decision analysts for guidance. At first, theory did not serve as a compass for the majority of these reasons.[20] Most of these efforts focused on trying to put a price tag on the anticipated benefits and recording the clinical results but in broader, patient-centered language. Pharmacoeconomics can be a great asset when it comes to making decisions about things like making sure the right medication is affordable and accessible to the right patients at the right time, comparing drugs in the same class or with similar mechanisms of action, and holding drug manufacturers accountable for their claims.[21] By using pharmacoeconomics correctly, pharmacists and pharmacy administrators will be able to make better, more educated decisions about the services and goods they offer. In the past, pharmacotherapy decisions were based only on clinical outcomes, such as safety and efficacy. However,

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24MAR1293

pharmacoeconomics has taught us that drug therapy should take into account three primary outcomes: clinical, economic, and humanistic. Everyone agrees that acquisition costs alone cannot be used to make good drug selection decisions today.[22] In conclusion, decision-making, evaluating patient affordability, ensuring timely pharmaceutical access, and comparing goods for illness treatment are all areas where applied pharmacoeconomics can be useful. In doing so, it will give evidence that runs counter to the marketing of some very expensive medical treatments. According to one school of thought, healthcare systems should aim to improve the health of the population as a whole while staying within a certain financial constraint, and the value of a new intervention can be determined by calculating the amount of money needed to achieve one more healthy person. In addition, the practitioners advocated for the use of quality-adjusted life years (QALYs) as a metric for health, a unit that combines life expectancy with the anticipated quality of that life in comparison to an unspecified ideal of health. The idea, however, was unsupported by evidence. It was noted that the real decision-makers were occupied with dealing with disease and its effects, rather than aiming to maximize collective health. A cost-effectiveness criteria was subsequently necessary as a result of this. The proposed and actual thresholds for societal assessment of health outcomes are inconsistent, arbitrary, and at odds with exploratory research.[21,22,23]

➢ *Handling the Results of Economic Evaluations*

Think about the four outcomes that could occur in a CEA. In the first triangle, we have "dominance" and the preferred treatment option, which is the medication with the lowest cost and higher health benefits. Secondly, in triangle IV, it is recommended that you not use the new drug because it is more expensive and has less of an effect. In the third and most typical scenario, the new medicine outperforms the standard (quadrant I) but is also more costly. In this circumstance, ICERs are used to determine if the greater benefits of the treatment are worth the extra costs, and the drug is then considered cost-effective. A predetermined ICER threshold value might serve as a defining factor in this case. In the fourth scenario, which is quite similar to the third, but with the new therapy and the standard in opposite positions (triangle III), the question becomes whether the additional benefits of the standard outweigh the additional costs of keeping it as the preferred treatment when a new, less effective but cheaper drug is available.[24]



Fig 1.Dealing with the Outcomes of Economic Evaluations is Illustrated

IV. LIMITS OF PHARMACOECONOMIC EVALUATION

Because of their relative youth, health economics, and pharmacoeconomics are still in the process of refining and evaluating their methods. Health economics has a lot of issues that make it hard to use in real life. From the assumptions taken, the selection of the comparator medicine, to the selective presentation of results, the entire process could be skewed. Because pharmaceutical corporations have an interest in the outcomes of the research they perform or fund, there is a bias in the publication of studies that are advantageous to the sponsoring companies. As a result, health economics is occasionally exploited for promotional purposes. To improve the efficacy and efficiency of prescribing, clinical pharmacologists should embrace pharmacoeconomic evaluation.[20,25]

➢ *Applications of Pharmacoeconomics*

The field of pharmacoeconomics offers valuable insights that healthcare practitioners can use in their practice. Drug policy and clinical decision-making are both aided by pharmacoeconomics. Once upon a time, most drug therapy decisions were based entirely on the clinical outcomes (such as safety and efficacy) linked with a treatment option. However, modern pharmacotherapy

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24MAR1293

includes evaluations of three fundamental outcome areas: economic, humanistic, and clinical. It has been common practice to calculate the potential financial benefits of a treatment option in the last fifteen to twenty years. These days, it's all about re-involving the patient in the decision-making process by factoring in the humanistic outcomes linked to treatment alternatives. Making medication selection decisions based on purchase prices alone is inappropriate in today's healthcare system.[26]

V. CONCLUSION

In conclusion, pharmacoeconomics is a vital field that studies the cost-effectiveness and accessibility of pharmaceutical treatments, aiding policymakers and healthcare providers in making informed decisions about patient care. Economic evaluations compare health interventions to determine costs and outcomes, with methods like cost-utility, cost-minimization, cost-benefit, and cost-effectiveness analyses playing key roles in assessing the financial, medical, and subjective impacts of treatments.

REFERENCES

[1]. Ahmad, A., Chang, J., Chung, H., Mohanta, G., Parimilakrishnan, S., & Patel, I. (2013). The role of pharmacoeconomics in current Indian healthcare system. *Journal of Research in Pharmacy Practice*, *2*(1), 3.

[2]. Drummond, M. F., Sculpher, M. J., & Torrance, G. W. (2005). Methods for the Economic Evaluation of Health Care Programmes. *Critical Assessment of Economic Evaluation*.

[3]. Bootman, J. L., Townsend, R. J., & Mcghan, W. F. (1996). *Principles of Pharmacoeconomics*. Harvey Whitney Books Co.

[4]. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Brief definition*. (n.d.).

[5]. Rajesh, B., Isha, B. P., & Chang, J. (2010). The Emerging role of pharmacoeconomics in the Indian scenario. *Indian J. Pharm. Pract*, *2*, 1–5.

[6]. Jana, S., & Mondal, P. (2005). Pharmacoeconomics: The need to sensitize undergraduate medical students. *Indian J Pharmacol*, *37*, 277–278.

[7]. Steed, L., Sohanpal, R., Todd, A., Madurasinghe, V. W., Rivas, C., Edwards, E. A., Summerbell, C. D., Taylor, S. J. C., & Walton, R. T. (2019). Community pharmacy interventions for health promotion: effects on professional practice and health outcomes. *The Cochrane Library*.

[8]. Touchette, D. R., Doloresco, F., Suda, K. J., Perez, A., Turner, S., Jalundhwala, Y., Tangonan, M. C., & Hoffman, J. M. (2014). Economic evaluations of clinical pharmacy services: 2006–2010. *Pharmacotherapy*, *34*(8), 771–793.

[9]. De Rijdt, T., Willems, L., & Simoens, S. (2008). Economic effects of clinical pharmacy interventions: A literature review. *American Journal of Health-System Pharmacy: AJHP: Official Journal of the American Society of Health-System Pharmacists*, *65*(12), 1161–1172. https://doi.org/10.2146/ajhp070506

[10]. Kosari, S., Deeks, L. S., Naunton, M., Dawda, P., Postma, M. J., Tay, G. H., & Peterson, G. M. (2021). Funding pharmacists in general practice: A feasibility study to inform the design of future economic evaluations. *Research in Social & Administrative Pharmacy: RSAP*, *17*(5), 1012–1016.

[11]. Walley, T., & Haycox, A. (1997). Pharmacoeconomics: basic concepts and terminology. *British Journal of Clinical Pharmacology*, *43*(4), 343–348.

[12]. Pontinha, V. M., Wagner, T. D., & Holdford, D. A. (2021). Point-of-care testing in pharmacies—An evaluation of the service from the lens of resource-based theory of competitive advantage. *Journal of the American Pharmacists Association: JAPhA*, *61*(2), e45–e54.

[13]. Rai, M., & Goyal, R. (2018). Pharmacoeconomics in Healthcare. In *Pharmaceutical Medicine and Translational Clinical Research* (pp. 465–472). Elsevier.

[14]. Eandi, M., Zara, G. P., & Pepa, C. D. (2000). Application of pharmacoeconomics to the use of antibiotics. *Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases*, *6*, 90–92.

[15]. Aberidoost, M., Nikfar, S., Abdollahiasl, A., & Dinarvand, R. (2013). Pharmaceutical supply chain risks: a systematic review. *Daru*, *21*(1).

[16]. Biswkarma, V. K., & Wadhawan, S. (2020). Emerging role of pharmacoeconomics into clinical trials and its outcomes: An overview. *Indian Journal of Pharmacy and Pharmacology*, *7*(2), 66–72.

[17]. Taylor, D., Knapp, M., & Kerwin, R. (2002). *Pharmacoeconomics in psychiatry*.

[18]. Henderson, L. W. (2000). Future developments in the treatment of end-stage renal disease: a North American perspective. *American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation*, *35*(4 Suppl 1), S106-16.

[19]. Lyles, A. (2008). L13 Recent trends in pharmacoeconomics: Needs and unmet needs. *European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences*, *34*(1), S12.

[20]. Trude, S., Au, M., & Christianson, J. B. (2006). Health plan pay-for-performance strategies. *The American Journal of Managed Care*, *12*(9), 537–542.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24MAR1293

[21]. Chisholm-Burns, M. A., Graff Zivin, J. S., Lee, J. K., Spivey, C. A., Slack, M., Herrier, R. N., Hall-Lipsy, E., Abraham, I., & Palmer, J. (2010). Economic effects of pharmacists on health outcomes in the United States: A systematic review. *American Journal of Health-System Pharmacy: AJHP: Official Journal of the American Society of Health-System Pharmacists*, *67*(19), 1624–1634.
[22]. Saokaew, S., Maphanta, S., & Thangsomboon, P. (2009). Impact of pharmacist's interventions on cost of drug therapy in intensive care unit. *Pharmacy Practice*, *7*(2).
[23]. McIntosh E, Luengo-Fernandez R. Economic evaluation. Part 1: Introduction to the concepts of economic evaluation in health care. *J Fam Plann Reprod Health Care*. 2006;32(2):107–112.
[24]. Gyrd-Hansen, D. (2005). Willingness to pay for a QALY: Theoretical and methodological issues. *PharmacoEconomics*, *23*(5), 423–432.
[25]. Torrance, G. W., & Feeny, D. (1989). Utilities and quality-adjusted life years. *International Journal of Technology Assessment in Health Care*, *5*(4), 559–575.
[26]. Clement, F. M., Harris, A., Li, J. J., Yong, K., Lee, K. M., & Manns, B. J. (2009). Using effectiveness and cost-effectiveness to make drug coverage decisions: A comparison of Britain, Australia, and Canada. *JAMA: The Journal of the American Medical Association*, *302*(13), 1437.